NYSE:TEVAPharmaceuticals
Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Margin Recovery Challenges High P/E Valuation Narrative
Teva Pharmaceutical Industries (NYSE:TEVA) has just posted its FY 2025 third quarter numbers, with revenue of US$4.5b and basic EPS of US$0.38, as the trailing 12 month line shows revenue of US$16.8b and basic EPS of US$0.62. Over recent quarters the company has seen revenue range from US$4.2b in Q4 2024 to US$4.5b in Q3 2025, while basic EPS moved from a loss of US$0.19 in Q4 2024 to a profit of US$0.38 in Q3 2025. This sets up a story where margin trends and the mix of products in late...